<DOC>
	<DOCNO>NCT00823680</DOCNO>
	<brief_summary>This 5 arm study evaluate efficacy safety RO5093151 RO5027838 patient type 2 diabetes mellitus stable dose metformin . After 4 week pre-randomization period glucose control , patient randomize one 5 group receive ) RO5093151 400mg po bid b ) RO5093151 10mg po bid c ) RO5027838 200mg po qd ) RO5027838 50mg po qd e ) placebo po bid 4 week . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study RO5093151 RO5027838 Patients With Type 2 Diabetes Mellitus Stable Dose Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>adult patient , 3565 year age ; type 2 diabetes &gt; =3 month ; treat &gt; =3 month stable dose metformin &gt; =1.5g/day maximum tolerate dose . history diabetic ketoacidosis ; currently previously treat insulin ; currently within previous 6 month treat thiazolidinedione dual peroxisome proliferator activate receptor ( PPAR ) agonist ; treat lipoproteinmodifying therapy within month screening .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>